Patheon® is a leading provider of drug substance and drug product services for the global biopharmaceutical industry. SEE AND Read More »

Looking for more info?

Contact Us

Leadership

James C. Mullen

Chief Executive Officer

Mr. Mullen is currently Chief Executive Officer of Patheon. He joined Patheon Inc. in 2011 as CEO and has continuously contributed to the company’s growth. Mr. Mullen led Patheon in 2012 as it acquired Banner Pharmacaps, a market leader in soft gelatin capsule technology. As a result of this acquisition, all of Banner’s manufacturing sites were structured under Patheon’s existing CMO business, aligning to the rest of its global network. In 2013, he led Patheon in a $2.6 billion transaction that merged Patheon with DSM Pharmaceutical Products, creating DPx. Mr. Mullen is also an Officer of DPx Holdings B.V.

Prior to joining Patheon, he served as CEO and President at Biogen Idec Inc. from 2003 to 2010, one of the world's largest biotechnology companies. Mr. Mullen was responsible for the merger of Biogen and Idec Pharmaceuticals, serving as CEO and President of Biogen from 2000 to 2002, and Chairman, CEO and President of Biogen until the merger was complete in 2003. Additionally, Mr. Mullen held various operating positions at Biogen prior to becoming CEO, including Vice President, Operations, and several manufacturing and engineering positions over a nine-year period at SmithKline Beecham.

Mr. Mullen possesses over 30 years of industry experience, ranging from biotechnology, pharmaceuticals to specialty chemicals, as well as extensive expertise in pharmaceutical and biotech manufacturing, engineering, sales, marketing, mergers and acquisitions. Currently, he serves on the Board of Directors for Perkins Elmer Inc. and as a trustee of The Rivers School. He previously served as Chairman of the Biotechnology Industry Organization. Mr. Mullen holds a Bachelor of Science in chemical engineering from Rensselaer Polytechnic Institute and a Master of Business Administration from Villanova University.

Stuart Grant

Stuart Grant

Chief Financial Officer and Executive Vice President of Finance and IT

Mr. Grant is currently Chief Financial Officer and Executive Vice President of Finance and IT at Patheon. Prior to this, he was Executive Vice President and Chief Financial Officer at Patheon, Inc. from 2012-2014. Prior to that, he served as Senior Vice President and Chief Financial Officer of BioCryst Pharmaceuticals, Inc., where he was a key player in the creation and execution of a company-wide strategy that stabilized, funded and enabled commercialization activities. Prior to BioCryst, Mr. Grant was Group Chief Financial Officer for Serono SA, Europe's largest biotechnology company. Over 12 years, he served in various senior operating and financial roles, including Finance Director for Swiss Manufacturing Operations and then General Manager of the company's manufacturing laboratories. Mr. Grant also spent 15 years in finance at Digital Equipment Corporation, and several years working as a tax consultant and senior auditor for Price Waterhouse in Glasgow, Scotland. Mr. Grant is also an Officer of DPx Holdings B.V.

Eric M. Sherbet

General Counsel and Secretary

With more than 25 years of experience representing global public and private equity backed companies in the pharmaceutical, professional services, engineering and construction, and telecommunication sectors, Mr. Sherbet is known for helping companies during periods of rapid growth and serving as a trusted advisor to management and boards of directors. Based in Boston, Mass., Mr. Sherbet serves as the General Counsel, overseeing all global legal affairs, corporate compliance and regulatory matters, in addition to his role as secretary of the company’s board of directors. Prior to joining the DPx senior leadership in 2014, he built the legal and compliance department of inVentiv Health, Inc. to support business concerns, including mergers and acquisitions, SEC filings, compliance and regulatory issues, and commercial deals. Mr. Sherbet earned his Bachelor of Science in commerce from the University of Virginia and a Juris Doctor from the New York University School of Law. Mr. Sherbet is also an Officer of DPx Holdings B.V.

Michael Lytton

Executive Vice President of Corporate Development and Strategy

Michael Lytton is currently Executive Vice President of corporate development and strategy at Patheon. Lytton also leads the company's product and technology business Banner Life Sciences. Prior to working for Patheon, Lytton spent three years as executive vice president, corporate and business development of Biogen Idec. From 2001 to 2008, Lytton was general partner with Oxford Bioscience Partners, a venture capital firm investing in therapeutic, diagnostic and life science tool companies. He practiced law from 1984 to 2000, and specialized in representing biomedical companies. He was a partner and a member of the executive committee of the law firm, Edwards Wildman Palmer, and was a partner of the law firm, Wilmer Hale. Lytton served as chairman of the board for Santhera Pharmaceuticals AG from 2004 to 2011, and served on various boards of many other academic, nonprofit, and private and public for-profit companies. Lytton holds an undergraduate degree from Princeton University, a Master of Science in epidemiology from the London School of Hygiene and Tropical Medicine at the University of London, U.K., where he was a Fulbright Scholar. Additionally, he earned a Juris Doctor from Harvard Law School. Mr. Lytton is also an Officer of DPx Holdings B.V.

Rebecca Holland New

Chief Human Resources Officer & Executive Vice President of Corp. Communications

Mrs. Holland New serves as Chief HR Officer and Executive Vice President of Human Resources and Corporate Communications at Patheon. She has a wealth of experience leading and developing business leadership, strategies and operational processes within growing global healthcare organizations. Before joining DPx Holdings, Mrs. Holland New held the same position at Patheon, Inc. Prior to that, she was Global Vice President of Human Resources at Bausch & Lomb. Before becoming Global VP, HR at Bausch & Lomb, she held global human resources leadership positions at the company’s business operations, talent, corporate and pharmaceutical business units as well as global research and development. Prior to joining Bausch & Lomb, Mrs. Holland New held human resources leadership positions at Novo Nordisk and Bristol-Myers Squibb. She currently serves on the Board of Trustees for the American Health Policy Institute and is active member with the HR Public Policy Association. Mrs. Holland New earned a master's degree in industrial and labor relations as well as a Bachelor of Science in economics, marketing and finance from Cornell University. In addition, she completed course work toward a Ph.D./Master of Science in organizational psychology from Columbia University and Rutgers University. Mrs. Holland New is also an Officer of DPx Holdings B.V.

Gary Shope

Chief of Staff

Mr. Shope serves as Chief of Staff at Patheon. Previously, he worked as an international business adviser for the Riyadh Technology Valley in Saudi Arabia. Mr. Shope has also served as Vice President and officer for the Research Triangle Park Foundation, as well as owner and operator of the internationally recognized Research Triangle Park. Furthermore, he directed international business development at the North Carolina Department of Commerce, including direct activity with two NC governors. In addition, Mr. Shope served as principal of Schottenstein, Zox, & Dunn, a law firm headquartered in Columbus, OH. He earned a Master of Public Administration from the University of North Carolina at Chapel Hill, and attended a one-year program at Yale University after graduating from West Virginia Wesleyan College.

Franco Negron

Sr. Vice President of the CMO business for North America

Mr. Negron serves as Senior Vice President, North America Commercial Operations and Global Integration within the global CMO business unit. Mr. Negron joined Patheon in November 2009 as Vice President and General Manager of the company’s operations in Puerto Rico. Mr. Negron has over 20 years’ experience in the pharmaceutical industry. He has served in various senior positions, including Global Vice President for Novartis Consumer Health, Over-the-Counter and Pharmaceutical Products with specific focus on global process improvement initiatives. Prior to joining Novartis, he also served as Vice President Manufacturing and Supply at Valeant Pharmaceuticals and Site General Manager for McNeil Consumer Healthcare. Mr. Negron holds a Bachelor of Science in electrical engineering from the University of Puerto Rico.

Antonio Magnelli

Sr. Vice President of the CMO business for Europe

Mr. Magnelli serves as Senior Vice President, European Commercial Operations within the global CMO business unit. He joined Patheon in July 2000 and has held progressively senior roles leading to his appointment in October 2008 to Executive Director and General Manager of the company’s facility in Monza, Italy. Mr. Magnelli has extensive experience in the pharmaceutical industry and began his career in 1993. Prior to joining Patheon, he held key roles in engineering at Sanofi-Aventis and is specialized in lyophilization. Mr. Magnelli holds a degree in chemical engineering from the University of Calabria, with a concentration in chemical processes.

Lukas Utiger

President, Drug Substance

Dr. Utiger is President of the Drug Substance network at Patheon. Most recently, he served as President and CEO of the DSM Pharmaceutical Products and DPx Fine Chemicals. Before joining DSM in 2013, Dr. Utiger served as Chief Operating Officer of the Bioscience Division at Lonza Group AG. Prior to that, he served as Chief Operating Officer of the company’s Life Science Ingredients Division, Head of the Exclusive Synthesis Business Sector, and Head of Research and Development for Exclusive Synthesis. He joined Lonza as an R&D Chemist in 1992 and advanced to Group Leader for fine chemicals in 1998. Dr. Utiger began his career at ICI Chemicals & Polymers Division in 1988. He earned his Ph.D. in Chemical Engineering at Imperial College, London.

Manja Bouman

President, Biologics

Ms. Bouman, is President of the Biologics business unit at Patheon. She is responsible for all operations and sales of the mammalian manufacturing business and biologics technology licensing, as well as the business line of BioSolutions for microbial based small and large molecule manufacturing.


Michael Lehmann

Michael Lehmann

President, Global PDS and EVP Global Sales & Marketing

Mr. Lehmann joined Patheon in 2012 as President, Global Pharmaceutical Development Services and was also later appointed the role of EVP, Global Sales and Marketing. Prior to joining Patheon, Mr. Lehmann served as Corporate Senior Vice President and General Manager of the Global Early Development business of Covance from 2005 to 2012, which is one of the world’s largest drug development services companies. In his role, he was responsible for global early development and P&L management; and key accomplishments included executive leadership in strategic deals between Covance, Lilly and Sanofi. Prior to joining Covance, Mr. Lehmann worked for 17 years at GE's Healthcare in key operational and management roles. His career started with a focus in client services, managing large call centers for both external customers and repair technicians. In 1998, he was tasked with assisting in the integration of the company’s MECON acquisition, operational and clinical performance optimization services. Mr. Lehmann progressed through various other comparable roles to emerge as the General Manager of the Multivendor Solutions business in 2003, where he was responsible for facilitating the upkeep and repair of other OEM diagnostic imaging equipment and accessories with complete P&L responsibilities. Mr. Lehmann holds a Master of Business Administration from Marquette University and a Bachelor of Science in mechanical engineering from the Catholic University of America.

Harry Gill

Sr. Vice President, Quality and Operational Excellence (OE)

Mr. Gill serves as Senior Vice President, Quality and Continuous Improvement. He joined Patheon in 2010 as Global Vice President of Operational Excellence and North America Vice President of Business Management, and was later promoted to his current position. He brings over 25 years of experience in quality, plant operations, technical services and operational excellence, having held various positions at Wyeth (now known as Pfizer Pharmaceuticals) and Baxter Healthcare Corporation. In addition, he has eight years of combined international experience in Asia and Puerto Rico. Mr. Gill received a Bachelor of Science in biology from Milligan College and a Master of Science in microbiology from East Tennessee State University.

Ray Guidotti

Senior Vice President, Global Technical Operations, Engineering, and Capacity

Mr. Guidotti serves as Senior Vice President of Global Technical Operations, Engineering, and Capacity Planning. He joined Patheon in 2009 and brings over 25 years of experience in engineering, facilities and project management. Mr. Guidotti started his pharmaceutical career with Bristol-Myers Squibb and since then, has held progressively senior technical leadership positions within the industry. Prior to joining Patheon, he spent a number of years in an industry consulting practice, supporting various pharmaceutical clients in developing and executing network strategy and business change projects. Mr. Guidotti holds a degree in marine engineering from NY Maritime College and is a registered professional engineer.

Knowledge Library


Please fill the below form to access requested content

First Name

Last Name

Company

Title

Email

Phone

Address Line 1

Address Line 2

City

Zip/ Postal Code

Country

Submit